Is Leap Therapeutics, Inc. (LPTX) a Buy, Sell, or Hold?
NASDAQ : LPTX
Leap Therapeutics, Inc.
$0.7696 USD
-$0.03 (-3.15%)
- Volume
- 848.47K
- Average Volume
- 22.41M
- Market Capitalization
- $31.86M
- P/E Ratio
- 1.20
- Dividend Yield
- 0.00%
- Price Target
- $5.50
- Year High
- $3.58
- Year Low
- $0.22
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.00
- Current Ratio
- $79.19
Company Overview
NASDAQ
Douglas E. Onsi
Biotechnology
Healthcare
LPTX
52
US
USD
Liquidity Metrics
0.00
79.19
79.19
4.39
0.00
Sales & Valuation
-$
152.42
0.97
-0.55
-0.33
Profitability
$0.0682
$4.82M
17655.50%
589.95%
23.83%
25.81%
P/E Metrics
1.20
0.00
0.00
Analyst Price Target & Rating
$5.50
$5.50
$5.50
0/5
4 Analysts
-86.01%
Financial Health Scores
-2.38
1/9
$78.92M
$87.38M
$3M
-$31.23M
Key Metrics (TTM)
$25.2M
120.60
-0.85
27.28
-46.86%
-35.50%
-43.99%
-250.02%
130037 days
Company Executives
| Name | Title |
|---|---|
| Douglas E. Onsi | Chief Financial Officer, General Counsel, Treasurer & Secretary, President, Chief Executive Officer & Director |
Poll Results
No votes yet today — be the first to share your view!
About Leap Therapeutics, Inc. (NASDAQ:LPTX) Stock
Leap Therapeutics, Inc. is a biopharmaceutical firm dedicated to discovering and advancing treatments for various cancers. At the forefront of its pipeline is DKN-01, a monoclonal antibody designed to block Dickkopf-related protein 1 (DKK1). This investigational therapy is currently undergoing several clinical trials, targeting a range of malignancies such as esophagogastric, hepatobiliary, gynecologic, and prostate cancers. Leap Therapeutics has also forged an option and licensing partnership with BeiGene, Ltd., granting them rights to develop and market DKN-01 across Asia (excluding Japan), Australia, and New Zealand. Established in 2011, the company initially operated as HealthCare Pharmaceuticals, Inc., before rebranding to Leap Therapeutics, Inc. in November 2015. Its corporate headqu ... arters are situated in Cambridge, Massachusetts.
Frequently Asked Questions
-
What is the current Leap Therapeutics, Inc. (LPTX) stock price?
-
Leap Therapeutics, Inc.(NASDAQ:LPTX) stock price is $0.7696 in the last trading session. During the trading session, LPTX stock reached the peak price of $3.58 while $0.2223 was the lowest point it dropped to. The percentage change in LPTX stock occurred in the recent session was --3.15% while the dollar amount for the price change in LPTX stock was -$0.03.
-
LPTX's industry and sector of operation?
-
The NASDAQ listed LPTX is part of Biotechnology industry that operates in the broader Healthcare sector.
-
Who are the executives of LPTX?
-
Douglas E. Onsi | Chief Financial Officer, General Counsel, Treasurer & Secretary, President, Chief Executive Officer & Director
|
|
|
| -
How many employees does LPTX have?
-
Number of LPTX employees currently stands at 52. LPTX operates from 47 Thorndike Street, Cambridge, MA 02141, US.
-
Link for LPTX official website?
-
Official Website of LPTX is: https://www.leaptx.com
-
How do I contact LPTX?
-
LPTX could be contacted at phone #617 714 0360 and can also be accessed through its website. LPTX operates from 47 Thorndike Street, Cambridge, MA 02141, US.
-
How many shares of LPTX are traded daily?
-
The average number of LPTX shares traded daily for last 3 months was 22.41M.
-
What is the market cap of LPTX currently?
-
The market value of LPTX currently stands at $31.86M with its latest stock price at $0.7696